Buy & Sell Citius Pharmaceuticals Inc (CTXR) – Citius Pharmaceuticals Inc Price Today
Aura AI Summary
CTXR (Citius Pharmaceuticals) is a clinical-stage biopharmaceutical company trading at $0.933, up 8.5% on the day. The stock shows strong analyst support with 5 Buy ratings, but fundamentals reflect its development-stage status with significant losses (-$36M net profit in 2025) and negative margins. Recent positive news includes the commercial launch of LYMPHIR™ generating $3.9M in initial revenue and securing $3.8M in non-dilutive funding.
The investment case hinges on successful commercialization of LYMPHIR and pipeline execution. While valuation appears modest (P/S: 2.84, P/B: 0.22), substantial execution risk remains given negative profitability and earnings misses. Analyst optimism contrasts with financial reality, creating a high-risk, high-potential opportunity dependent on revenue acceleration and path to profitability.
Key Stats
- $17.23MMarket Cap
- HealthSector
- -29.17%3M Drawdown
- $11.34MEnterprise Value
- -Dividend Yield
- 100% Buy | 0% SellTrading Activity
- 1 daysTypical Hold Time
52W Low: $0.67
23 Feb 2026
52W High: $2.21
03 Jul 2025
Citius Pharmaceuticals Inc (CTXR) is currently valued at a market capitalization of $17.23M, with an enterprise value of $11.34M. Over the past 52 weeks, Citius Pharmaceuticals Inc has traded between a low of $0.67 and a high of $2.21, highlighting its annual price range. Over the past three months, Citius Pharmaceuticals Inc has recorded a drawdown of -29.17%, reflecting recent price volatility. On average, investors hold Citius Pharmaceuticals Inc for approximately 1 days, indicating typical investor behavior on the platform.
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Technical Indicators
|
|
|
Overall Summary
Bearish (14)Neutral (4)Bullish (7)
News
People also bought
US Stocks risk is managed by PT PG Berjangka which has a license from the Badan Pengawas Perdagangan Berjangka Komoditi (BAPPEBTI), and your investment is guaranteed by the Jakarta Futures Exchange (JFX) and the Indonesian Clearing House (KBI). Read our product’s Terms and Conditions. View Terms and Conditions